Lantheus (LNTH) said Wednesday its radiodiagnostic MK-6240 to treat Alzheimer's disease met its co-primary endpoints in two trials evaluating its sensitivity and specificity.
The results from the two trials will back a new drug application with the US Food and Drug Administration, which is expected to be filed in Q3, the company said.
MK-6240 was designed to complement Lantheus' imaging agent NAV-4694, which is in phase 3 development and is used in academic and industry-led investigational trials for Alzheimer's disease, the company said.
The company's shares were down 0.5% in recent trading.
Price: 103.00, Change: -0.96, Percent Change: -0.93
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。